ibuprofen (Ibuprof von CT 2% / Ibuprof von CT / Ibupan)

One-month suspension for spendthrift vet.

Loeb Josh J

Transient HA-100 exposure improves aggregate uniformity and cell-cell contact stability in suspension human pluripotent stem cell cultures.

Khurana Preeti P, Azad Amar J AJ, Kolundzic Nikola N, Liovic Mirjana M et al.

Human pluripotent stem cell (hPSC) manufacturing workflows frequently rely on suspension aggregation, yet inter-line and batch-to-batch variability in aggregate formation can compromise process consistency and downstream differentiation performance. We evaluated whether a short exposure to HA-100, a small-molecule inhibitor of protein kinase A and protein kinase C signaling, could be used as an upstream process intervention to improve aggregate uniformity without compromising hPSC identity or developmental competence. Nine hPSC lines, including human embryonic stem cell and induced pluripotent stem cell lines, were examined in suspension culture. HA-100 was applied during the first 24 h of aggregation. Aggregate morphology and size distribution were assessed across lines. To investigate the cellular basis of this effect, we generated an mCherry-TJP1 reporter hESC line, which enabled live visualization of junction dynamics, including responses under calcium-depleted conditions and recovery of transepithelial electrical resistance. HA-100 treatment promoted more compact and spherical aggregates, increased aggregate size into a narrower range across lines, and reduced overall variability relative to medium alone. Across the nine-line panel, HA-100-treated aggregates fell within an empirically definesd size range of 25.37-33.95 x 10^-4 mm^3 after 24 h of suspension culture, providing a practical benchmark for process monitoring. In calcium-depleted conditions, HA-100 delayed disruption of intercellular contacts and accelerated recovery of transepithelial electrical resistance, consistent with improved junctional resilience. Transient exposure to HA-100 did not abolish pluripotency marker expression or tri-lineage differentiation capacity. These data support HA-100 as a practical upstream intervention to reduce aggregate heterogeneity in suspension hPSC cultures and improve reproducibility in manufacturing-oriented workflows requiring consistent aggregation.

Oral and Maxillofacial Surgeon Accuracy in Anticipating Supplemental Opioid Use Following Third Molar Extraction.

van den Dries Sierra R SR, Panchal Neeraj N, Wang Steven S, Habib Rania A RA et al.

Accurately identifying patients who will require opioids after third molar extraction could improve pain management while supporting opioid stewardship. This study evaluated surgeon accuracy in predicting supplemental opioid use following treatment with ibuprofen and acetaminophen. Patients (N=85) undergoing third molar extraction were treated with a standardized analgesic regimen of ibuprofen+acetaminophen, with supplemental opioid if needed. Four surgeons independently reviewed preoperative radiographs, assessed surgical difficulty using the Pederson scale, and rated the likelihood of supplemental opioid use on a 5-point Likert scale. Inter-rater reliability was assessed using intraclass correlation coefficients (ICC). The relationship between surgeon ratings and postoperative opioid use was evaluated using logistic regression and receiver operating characteristic (ROC) analysis. Seventeen patients used supplemental opioid analgesics. Inter-rater reliability among surgeons was moderate (ICC3=0.606, 95%CI: 0.505-0.700), while reliability of the average rating across surgeons was good (ICC3k = 0.860, 95% CI: 0.804-0.903). Median surgeon rating was not associated with postoperative opioid use (OR: 0.800, 95% CI: 0.414-1.51, p=0.496) and demonstrated poor discrimination (AUC: 0.551, 95% CI: 0.392-0.710). Surgeon ratings were positively associated with Pederson score (β=0.073, 95%CI: 0.050-0.096; p<0.001). Surgeons demonstrated moderate agreement, but these assessments did not accurately identify patients who ultimately required supplemental opioids. Surgeon judgments appeared to be influenced by anticipated surgical difficulty. Clinicians should follow current recommendations against routine "just-in-case" opioid prescribing after third molar extraction. Future studies should focus on identifying clinical and biological predictors of inadequate analgesic response to NSAIDs to support individualized pain management strategies.

Ibuprofen and Palmitic Acid-Based Solvent Exchange-Induced In Situ Forming Matrices With Gentian Violet for Oropharyngeal Candidiasis and Periodontitis Treatment.

Phaechamud Thawatchai T, Phattanawasin Panadda P, Senarat Setthapong S, Puapermpoonsiri Utsana U et al.

Gentian violet (GV) is a broad-spectrum antimicrobial agent with documented efficacy against oropharyngeal candidiasis and periodontal pathogens, but its clinical use is limited by poor local retention. In situ forming matrices (ISMs) offer a promising strategy for sustained, localized drug delivery. This study aimed to develop and evaluate GV-loaded ISMs using ibuprofen (IBU) and palmitic acid (PA) as dual-function matrix-forming agents in DMSO and NMP solvents for the localized treatment of oropharyngeal candidiasis and periodontitis. ISM formulations were prepared by simple mixing and characterized for viscosity, rheological behavior, injectability, mechanical properties, and in situ matrix formation. In vitro drug release of GV and IBU was quantified by a validated simultaneous HPLC method using an ACE C18 column with UV detection at 590 and 222 nm, respectively. Drug-release kinetics were modeled using zero-order, first-order, Higuchi, Korsmeyer-Peppas, and Peppas-Sahlin models. Antimicrobial activity against Staphylococcus aureus, Candida albicans, C. tropicalis, and Porphyromonas gingivalis was assessed by agar diffusion over 15 days. Molecular interactions were investigated using density functional theory (DFT) calculations at the B3LYP-D3BJ/6-31G(d,p) level. All formulations showed Newtonian-flow behavior and acceptable injectability (0.78-1.50 N). GV and IBU release followed the Peppas-Sahlin model, with NMP-based systems releasing GV and IBU faster due to more porous matrix architecture, while DMSO-based systems formed denser matrices with slower release. All GV-containing formulations maintained antimicrobial inhibition zones for up to 15 days. DFT calculations revealed strong GV-IBU (-1.63 eV) and GV-PA (-1.53 eV) binding energies, supporting sustained drug entrapment. GV-loaded IBU/PA-based ISMs demonstrate sustained antimicrobial efficacy for up to 15 days with solvent-dependent release behavior. These systems show potential as localized, single-injection therapies for oral infections. Stability evaluation and in vivo biocompatibility studies are identified as necessary future steps.